<DOC>
	<DOC>NCT02904850</DOC>
	<brief_summary>Several arguments are in favor of a therapeutic monitoring for the erlotinib, therefore, a pharmacokinetic (PK) has been prepared using data from the literature. This model must be validated at concentrations achieved in practice. This is a preliminary study before the implementation of a randomized trial confirming the therapeutic monitoring of erlotinib through this model.</brief_summary>
	<brief_title>Validation of a Kinetic Model of Erlotinib</brief_title>
	<detailed_description />
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>All patients receiving treatment with erlotinib monotherapy for locally advanced or metastatic NSCLC either first line in patients with an activating mutation of the receptor EGFR or patients with stable disease after 4 cycles of standard firstline chemotherapy with platinum or after failure of at least one prior chemotherapy regimen Age&gt; 18 years Subject has signed an informed consent Treatment initiated for at least 7 days or dosage changed for at least 7 days Contraindication to the use of drug Subject to exclusion period (as determined by a previous study or in progress) Inability to give informed information (subject in emergency situations, difficulties in understanding the subject, ...) Subject under judicial protection Subject under tutorship or curatorship Pregnancy (and woman of childbearing age without contraception) Breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>locally advanced or metastatic</keyword>
	<keyword>erlotinib monotherapy</keyword>
</DOC>